Solstice Oncology, Inc.

Biotechnology · BOSTON, MA

BiotechnologySEC Form D

Solstice Oncology, Inc. filed a Form D with the U.S. Securities and Exchange Commission on March 9, 2026, reporting $121,260,306 raised toward a $298,400,851 offering.

Incorporated in Delaware and based in BOSTON, MA, it operates in the Biotechnology sector.

Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that Solstice Oncology, Inc. has raised capital from private investors.

Browse more recently funded companies in Biotechnology.

Executives & Directors

  • CAROLINE LOEWExecutive Officer · Director · Promoter
  • EMILY MINKOWDirector
  • ANDREW LEVINDirector
  • MORGAN HALLERDirector
  • JULIE GRANTDirector
  • Maiken Keson-BrookesExecutive Officer
  • David FeltquateExecutive Officer

Recently funded in Biotechnology

Other companies that recently filed a Form D

$3.2MRaised

Goldenrod Therapeutics, Inc.

BiotechnologyHOUSTON, TX
$10.0MRaised

Human Biotech, Inc.

BiotechnologyCAMBRIDGE, MA
$1.0MRaised

Optimeos Life Sciences, Inc.

BiotechnologyPRINCETON, NJ
$2.5MRaised

BioStem Technologies, Inc.

BiotechnologyPOMPANO BEACH, FL
$10.0MRaised

Senti Biosciences Holdings, Inc.

BiotechnologySouth San Francisco, CA
Solstice Oncology, Inc. raised $121.3M — SEC Form D